

FORM PTO-1449 (Rev. 2-32)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 36193	SERIAL NO. 10/536,584
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT: MESSADEK, Jallal			
(Use several sheets if necessary)		FILING DATE: April 7, 2006		GROUP: 1615 Conf. 9204	

### U.S. PATENT DOCUMENTS

EXAM. INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		5	8	8	0	0	9	8	9/3/99	Haussinger			

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							PUB DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
		0	7	8	1	5	5	4	02.07.96	EPO			YES	NO
		9	8	1	9	6	9	0	14.05.98	WO			X	
		9	5	1	5	7	5	0	15.06.95	WO			X	
		9	7	3	8	6	8	5	23.10.97	WO			X	
		0	3	4	7	8	6	4	27.12.89	EPO			X	
		0	0	2	5	7	6	4	11.05.00	WO			X	
		9	7	0	6	7	9	5	27.02.97	WO			X	
		2	1	0	1	2	2	B	28.09.92	HU				X
1	0	3	2	1	9	8	4	23.05.00	JP				X (ab- stract only)	
		0	0	5	1	5	9	6	08.09.00	WO			X	
		0	3	4	9	9	0	2	10.01.90	EPO			X	

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Savi et al., Abstract from Entrez-PubMed web page entitled "SR 121787, a new orally active fibrinogen receptor antagonist," Thromb Haemost, 1998 Sep;80(3):469-76., 1 page
		Banno et al., Abstract from Entrez-PubMed web page entitled "Antiaggregatory, antithrombotic effects of MS-180, a novel platelet glycoprotein IIb/IIIa receptor antagonist," Eur J Pharmacol., 1999 Feb 19;367(2-3):275-82., 1 page
		Ramjit et al., Abstract from Entrez-PubMed web page entitled "Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis," J Pharmacol Exp Ther., 1993 Sep;266(3):1501-11, 2 pages
		Hoffmann et al., Abstract from Entrez-PubMed web page entitled " Prevention of thrombosis and enhancement of thrombolysis in rabbits by SR 121787, a glycoprotein II/III antagonist," J Pharmacol Exp Ther., 1998 Aug;286(2):670-5., 1 page
		Packham, Abstract from Entrez-PubMed web page entitled "Role of platelets in thrombosis and hemostasis." Can J Physiol Pharmacol., 1994 Mar;72(3):278-84., 1 page
		Lynch et al., Abstract from Entrez-PubMed web page entitled " Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383," J Pharmacol Exp Ther., 1995 Jan;272(1):20-32., 2 pages
		Katada et al., Abstract from Entrez-PubMed web page entitled "The in vitro and in vivo pharmacological profiles of a platelet glycoprotein IIb/IIIa antagonist, NSL-9403," Thromb Res., 1997 Oct 1;88(1):27-70., 1 page

EXAMINER: Initial if changes made in this sheet are in conformance with the communication with the examiner; initial if changes made through J.V./ citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**ALL REFERENCES CONSIDERED EXCEPT WHERE REVERSED THROUGH J.V./**

FORM PTO-1449 (Rev. 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 36193	SERIAL NO. 10/536,584
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT: MESSADEK, Jallal	
(Use several sheets if necessary)		FILING DATE: April 7, 2006	GROUP: 1615 Conf. 9204

### U.S. PATENT DOCUMENTS

EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES
							NO

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Ogawa et al., Abstract from Entrez-PubMed web page entitled "Antiplatelet and antithrombotic effects of orbofiban, a new orally active GPIIb/IIIa antagonist, in guinea pigs," Thromb Res., 2000 Mar 1;97(5):307-15., 1 page
		Zapadniuk, Abstract from Entrez-PubMed web page entitled "Cholagogic effect of trimethylglycine in normal animals of different ages and in experimental atherosclerosis," Biull Eksp Biol Med., 1987 Jul;104(7):30-2., 2 pages
		Panteleimonova, Abstract from Entrez-PubMed web page entitled "Effect of trimethylglycine on lipid metabolism in experimental atherosclerosis in rabbits," Farmakol Toksikol, 1983 Jul-Aug;46(4):83-5., 1 page
		Fazio et al., "Treatment of Human Atherosclerosis with Betaine," Minerva Med, 1961 Apr 25, pp. 1511-1516, XP-000853747
		P.H. List et al., "Hagers Handbuch Der Pharmazeutischen Praxis," 1972, Springer Verlag, Berlin Heidelberg, New York, page 431, XP-002123167
		Wilcken et al., "The natural history of vascular disease in homocystinuria and the effects of treatment," J. Inher. Metab. Dis. 20(1997) 295-230.
		Betaine for Homocystinuria, The Medical Letter, Vol 39, Issue 993, January 31, 1997, page 12, XP-000853853
		Reynolds, Betaine Hydrochloride, Matindale, The Extra Pharmacopoeia, 1996, Royal Pharmaceutical Society, London, page 1679, XP-002123168.
		1225. Betaine, The Merck Index, 1996 Merck and Co., Whithouse Stations, NJ, p. 198, XP-002123169
		Mar et al., Abstract from Entrez-PubMed web page entitled "Betaine in wine: answer to the French paradox?" Med Hypotheses, 1999 Nov;53(5):383-5., 2 pages
		Salamone et al, "Changes in blood coagulation in experimental subacute poisoning with p-dichlorobenzene. The influence of some lipotropic factors," Journal, Answer 13 of 13, Copyright 2003, ACS, 1 page
		Vinson et al., "New Drug Approvals of 1996-Part 3," Drug Topics, March 17, 1997, University of Mississippi School of Pharmacy, pp. 72-81.
		Matthews et al., "An indirect response model of homocysteine suppression by betaine: optimising the dosage regimen of betaine in homocystinuria," 2002 Blackwell Scient Ltd Br J Clin Pharmacol, 54, 140-146.
		Schwahn et al, "Pharmacokinetics of oral betaine in healthy subjects and patients with homocystinuria," 2003 Blackwell Scient Ltd Br J Clin Pharmacol, 55, 6-13.
		Matthews, Pharmacokinetics from <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1234567/">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1234567/</a> Clinical Pharmacology, pp. 1-2. (no date)
		Matthews, Pharmacokinetics from <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1234567/">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1234567/</a> Clinical Pharmacology, pp. 1-2. (no date)

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance. Initial if reference is considered relevant to this application. Initial if reference is considered relevant to this application. /J.V./

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH**

FORM PTO-1449 (Rev. 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 36193	SERIAL NO. 10/536,584
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)		APPLICANT: Jallal Messadek	
		FILING DATE: April 7, 2006	GROUP: 1615 CONF. NO: 9204

### U.S. PATENT DOCUMENTS

EXAM. INITIAL	DOCUMENT NUMBER	INVENTOR NAME	CLASS	SUB- CLASS	ISSUE DATE (PATENT); PUBLICATION DATE (PUBLISHED APPLICATION); OR FILING DATE (NON-PUBLISHED APPLICATION)
	6 2 8 7 7 6 5	Cubicciotti			September 11, 2001
	US 2002/0034757	Cubicciotti			March 21, 2002
	5 9 2 8 1 9 5	Malamud et al.			July 27, 1999
	6 3 9 9 7 8 5	Murphy et al.			June 4, 2002
	6 8 5 5 7 3 4	Messadek			February 15, 2005

### FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
						YES NO

### OTHER DOCUMENTS (Including Publisher, Author, Title, Relevant Pages, and Date and Place of Publication)

		Bandfield et al., "Naproxen, Naproxen Sodium, and Naproxen Betainate Sodium Monohydrate Salts," Pharmaceutics 1, April 14, 2001, pp. 1-5
		van Hecken et al., Abstract from Entrez-PubMed web page entitled "Effect of clopidogrel on naproxen-induced gastrointestinal blood loss in healthy volunteers," Drug Metabol Drug Interact, 1998;14(3):193-205., 1 page
		EC-Naprosyn, Naprosyn, Anaprox, Naprosyn, Rx Only, Roche Pharmaceuticals, Copyright 1999-2004 by Roche Laboratories Inc., pp. 1-20
		Environmental and Health Assessment of Substances in Household Detergents and Cosmetic Detergent Products, Environment Project, 615, 2001, 6.1 Betaines, <a href="http://www2.mst.dk/common/Udgivramme/Frame.asp?pg=http://www2.mst.dk/udgiv/Publications/2001/87-7944-596-9/html/helepubl_eng.htm">http://www2.mst.dk/common/Udgivramme/Frame.asp?pg=http://www2.mst.dk/udgiv/Publications/2001/87-7944-596-9/html/helepubl_eng.htm</a> , 1 page
		<del>NIAID Home/Anti-HIV/Chemical Compound Search/Anti-HIV/Chemical Compound Results</del> <a href="http://chemdb.niaid.nih.gov/struct_search/all/url_search.asp?aids_no=008188">http://chemdb.niaid.nih.gov/struct_search/all/url_search.asp?aids_no=008188</a> , 1 page (no date)
		Wyrick P.B. et al., The Microbicidal Agent C31G Inhibits Chlamydia Trachomatis Infectivity in vitro., <u>Antimicrob Agents Chemother</u> , 1997 June, 41(6): 1335-44, PMID: 9174195, 1 page
		Thompson, K.A. et al., Assessment of the Anti-Microbial Agent C31G as a Spermicide: Comparison with Nonoxynol-9, <u>Contraception</u> , 1996 May, 53(5): 313-8, PMID: 8724622, 1 page

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.V./**

FORM PTO-1449 (Rev. 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 36193	SERIAL NO. 10/536,584
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT: Jallal Messadek	
(Use several sheets if necessary)		FILING DATE: April 7, 2006	GROUP: 1615
		CONF. NO:9204	

### U.S. PATENT DOCUMENTS

EXAM. INITIAL	DOCUMENT NUMBER	INVENTOR NAME	CLASS	SUB- CLASS	ISSUE DATE (PATENT); PUBLICATION DATE (PUBLISHED APPLICATION); OR FILING DATE (NON-PUBLISHED APPLICATION)
	US 2004/0033223	Messadek			February 19, 2004
	4 0 6 6 7 5 6	Orr et al.			January 3, 1978
	4 7 0 3 0 4 5	Guinot			October 27, 1987
	5 8 7 6 7 8 0	Vertanen			March 2, 1999
	5 9 6 1 9 9 9	Bimczok et al.			October 5, 1999

### FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
						YES NO

### OTHER DOCUMENTS (Including Publisher, Author, Title, Relevant Pages, and Date and Place of Publication)

		Rogers J.S., Abstract from Entrez-PubMed web page entitled "Hypercoagulable states," W V Med J., 1993 Feb;89(2):61-3, 1 page
		Nielsen H.K., Abstract from Entrez-PubMed web page entitled "Pathophysiology of venous thromboembolism," Semin Thromb Hemost, 1991;17 Suppl 3:250-3, 1 page
		Silver et al., Abstract from Entrez-PubMed web page entitled "The caput medusae of hypercoagulability," J. Vasc. Surg., 2000 Feb;31(2):396-405, 1 page
		Swan M.A., "Improved Preservation of the Ram Spermatozoan Plasma Membrane using Betaine in the Primary Fixative," J. Microsc., 1997 Sept., 187(pt 3): 167-9, PMID: 9351233, 1 page
		Thomas, K.C. et al., "Effects of Particulate Materials and Osmoprotectants on Very-High-Gravity Ethanolic Fermentation by Saccharomyces Cerevisiae, Appl Environ Microbiol, 1994 May, 60(5): 1519-24, PMID: 801734, 1 page
		Chambers, S. et al., The Osmoprotective Properties of Urine for Bacteria: The Protective Effect of Betaine and Human Urine Against Low pH and High Concentrations of Electrolytes, Sugars, and Urea, J. Infect Dis., 1985 Dec, 152(6): 1308-16, PMID: 3905988, 1 page
		Smith, L.T., Role of Osmolytes in Adaptation of Osmotically Stressed and Chill-Stressed Listeria Monocytogenes Grown in Liquid Media and on Processed Meat Surfaces, Appl Environ Microbiol, 1996 Sept., 62(9): 3088-93, PMID: 8795194, 1 page
		Peddie B.A. et al., Is the Ability of Urinary Tract Pathogens to Accumulate Glycine Betaine a Factor in the Virulence of Pathogenic Strains?, J. Lab. Clin. Med., 1996 Oct., 128(4): 417-22, PMID: 8833891, 1 page
		Koskinen, E. et al., A Preliminary Study on the Use of Betaine as a Cryoprotective Agent in Deep Freezing of Stallion Semen, Zentralbl Veterinarmed A., 1989 Feb., 36(2): 110-4, PMID: 2501949, 1 page
		Swan M.A., Improved Preservation of Ultrastructural Morphology in Human Spermatozoa Using Betaine in the Primary Fixative, Int. J. Androl., 1997 Feb 20(1): 45-54, PMID: 9202990, 1 page

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.V./**

FORM PTO-1449 (Rev. 2-32)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO. 36193	SERIAL NO. 10/536,584	
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT							APPLICANT: Jallal Messadek		
		(Use several sheets if necessary)							FILING DATE: April 7, 2006	GROUP: 1615	CONF. NO: 9204

## U.S. PATENT DOCUMENTS

EXAM. INITIAL		DOCUMENT NUMBER							INVENTOR NAME	CLASS	SUB-CLASS	ISSUE DATE (PATENT); PUBLICATION DATE (PUBLISHED APPLICATION); OR FILING DATE (NON-PUBLISHED APPLICATION)
		6 2 3 5 3 1 1							Ullah et al.			May 22, 2001
		6 3 5 5 1 6 6							Amarasinghe et al.			March 12, 2002
		6 4 7 6 0 0 6							Flashner-Barak et al.			November 5, 2002

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							PUBLICATION DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
													YES	NO
		DE 19910682							September 21, 2000	Germany			X (abstract only)	
		JP 2000-143486							May 23, 2000	Japan			X (abstract only)	
		BE 1012546 (09900164)							December 5, 2000	Belgium			X (abstract only)	
		BE 1012712 (09900403)							February 6, 2001	Belgium			X (abstract only)	
		BE 2003/0248							April 17, 2003	Belgium			X (abstract only)	
		FR 77 29075 (2 403 799)							September 27, 1977	France			X (Google translation only)	

## OTHER DOCUMENTS (Including Publisher, Author, Title, Relevant Pages, and Date and Place of Publication)

			Uake Vu/ 02/24/2010

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.V./